Hadasit Medical Research Services and Development Ltd.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Emory University

Hilla Giladi

Amos B Oppenheim

Franck Amblard

Eithan Galun

Bryan D Cox

Idit Azar

Daniel Goldenberg

Zohar Shmuelian

Dayana Yaish

Chofit Chai

Nofar Rosenberg

Simi Kobi

Simi Koby

Mali Ketzinel Gilad

Evelyn Zeira

Sagit Arbel Alon

Yael Hantz

Alina Simerzin

The present invention provides compositions having one or more agents capable of increasing expression of one or more endogenous tumor suppressive mi RNAs in one or more producing cells, such that the endogenous mi RNAs can affect one or more target cancer cells. Further provided are method and uses thereof for treating cancer.

Tumor suppressive microRNAs for cancer therapy

The present invention provides miR-122* as a functional microRNA molecule, compositions comprising the same and uses thereof for treatment of various conditions, such as, cancer. Further provided are methods for increasing the expression, stability and/or activity of p53 in a target cell or method for inducing cancer cell death, the methods comprising introducing into the cell a miR-122* polynucleotide molecule or a vector expressing or encoding the same.

miR-122* as an active micro-RNA, compositions comprising the same and uses thereof

A method for administering the HAV vaccine to a subject by absorption through a mucosal tissue, particularly through the mucosa of the rectum. The method of the present invention enables the HAV vaccine to be administered to the subject rectally, for example as a suppository or other rectal dosage form, and to successfully immunize the subject against HAV. Thus, the present invention overcomes problems of background art methods of administration, such as systemic administration by injection for example, which require needles, and which are difficult and expensive to perform.

Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine

The invention relates to an expression vector, the nucleic acid sequence of which comprises a promoter that is capable of controlling, when the vector is in a bacterial host and the temperature is lowered to below about 20.degree. C., the production of recombinant peptide or protein encoded by a gene contained within the vector. The invention also relates to host cells containing the vectors and to a method of producing a recombinant protein.

Vectors and transformed host cells for recombinant protein production at

Growing community of inventors

Mevasseret Zion, Israel

Hilla Giladi